Pfizer Inc (NYSE: PFE) has reported E.P.S. of $0.07 for its fourth fiscal quarter (ending December 31) versus $-0.59 for the same period a year ago — a decline of -112%. For the latest four quarters through December 31, E.P.S. were $1.42 compared to $0.38 a year ago — an increase of 274%.
Recent Price Action
Pfizer Inc (NYSE: PFE) stock closed at $25.87 on 2/4/25 after a modest decline of -1.3%. Moreover, trading volume in this decline was unusually high at 172% of normal. The stock has declined -3.7% during the last week and has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Pfizer has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Pfizer has a good Appreciation Score of 82 but a poor Power Rating of 25, resulting in the Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment